|
1
|
Ricketts CJ, De Cubas AA, Fan H, Smith CC,
Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, et al:
The cancer genome atlas comprehensive molecular characterization of
renal cell carcinoma. Cell Rep. 23:36982018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
Cancers in 185 Countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferlay J, Colombet M, Soerjomataram I,
Dyba T, Randi G, Bettio M, Gavin A, Visser O and Bray F: Cancer
incidence and mortality patterns in Europe: Estimates for 40
countries and 25 major cancers in 2018. Eur J Cancer. 103:356–387.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Padala SA and Barsouk A, Thandra KC,
Saginala K, Mohammed A, Vakiti A, Rawla P and Barsouk A:
Epidemiology of renal cell carcinoma. World J Oncol. 11:79–87.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vasudev NS, Wilson M, Stewart GD, Adeyoju
A, Cartledge J, Kimuli M, Datta S, Hanbury D, Hrouda D, Oades G, et
al: Challenges of early renal cancer detection: Symptom patterns
and incidental diagnosis rate in a multicentre prospective UK
cohort of patients presenting with suspected renal cancer. BMJ
Open. 10:e0359382020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bradley AJ, Maskell GF, Mannava A, Pollard
A and Welsh T: Routes to diagnosis and missed opportunities in the
detection of renal cancer. Clin Radiol. 76:129–134. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yin Q, Xu H, Zhong Y, Ni J and Hu S:
Diagnostic performance of MRI, SPECT, and PET in detecting renal
cell carcinoma: A systematic review and meta-analysis. BMC Cancer.
22:1632022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Usher-Smith J, Simmons RK, Rossi SH and
Stewart GD: Current evidence on screening for renal cancer. Nat Rev
Urol. 17:637–642. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rossi SH, Blick C, Handforth C, Brown JE
and Stewart GD: Essential research priorities in renal cancer: A
modified delphi consensus statement. Eur Urol Focus. 6:991–998.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang S, Zhang E, Long J, Hu Z, Peng J,
Liu L, Tang F, Li L, Ouyang Y and Zeng Z: Immune infiltration in
renal cell carcinoma. Cancer Sci. 110:1564–1572. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Díaz-Montero CM, Rini BI and Finke JH: The
immunology of renal cell carcinoma. Nat Rev Nephrol. 16:721–735.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kartikasari AER, Huertas CS, Mitchell A
and Plebanski M: Tumor-Induced inflammatory cytokines and the
emerging diagnostic devices for cancer detection and prognosis.
Front Oncol. 11:6921422021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lan T, Chen L and Wei X: Inflammatory
cytokines in cancer: Comprehensive Understanding and Clinical
Progress in Gene Therapy. Cells. 10:1002021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zeng Q, Sun S, Li Y, Li X, Li Z and Liang
H: Identification of therapeutic targets and prognostic biomarkers
among CXC chemokines in the renal cell carcinoma microenvironment.
Front Oncol. 9:15552020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee MH, Laajala E, Kreutzman A, Järvinen
P, Nísen H, Mirtti T, Hollmén M and Mustjoki S: The tumor and
plasma cytokine profiles of renal cell carcinoma patients. Sci Rep.
12:134162022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gudbrandsdottir G, Aarstad HH, Bostad L,
Hjelle KM, Aarstad HJ, Bruserud Ø, Tvedt THA and Beisland C: Serum
levels of the IL-6 family of cytokines predict prognosis in renal
cell carcinoma (RCC). Cancer Immunol Immunother. 70:19–30. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vargová D, Dargaj J, Fraňová S, Dohál M,
Ľupták J, Švihra J, Briš L, Grendár M and Šutovská M:
Immunobiochemical profile of clear cell renal cell carcinoma
(ccRCC): A preliminary study. Gen Physiol Biophys. 42:387–401.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Amin MB, Greene FL, Edge SB, Compton CC,
Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and
Winchester DP: The Eighth Edition AJCC Cancer Staging Manual:
Continuing to build a bridge from a population-based to a more
‘personalized’ approach to cancer staging. CA Cancer J Clin.
67:93–99. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Moch H, Cubilla AL, Humphrey PA, Reuter VE
and Ulbright TM: The 2016 WHO classification of tumours of the
urinary system and male genital Organs-Part A: Renal, penile, and
testicular tumours. Eur Urol. 70:93–105. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Faul F, Erdfelder E, Buchner A and Lang
AG: Statistical power analyses using G*Power 3.1: Tests for
correlation and regression analyses. Behav Res Methods.
41:1149–1160. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Colotta F, Allavena P, Sica A, Garlanda C
and Mantovani A: Cancer-related inflammation, the seventh hallmark
of cancer: Links to genetic instability. Carcinogenesis.
30:1073–1081. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
de Vivar Chevez AR, Finke J and Bukowski
R: The Role of Inflammation in Kidney Cancer. Adv Exp Med Biol.
816:197–234. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gradin A, Andersson H, Luther T, Anderberg
SB, Rubertsson S, Lipcsey M, Åberg M, Larsson A, Frithiof R and
Hultström M: Urinary cytokines correlate with acute kidney injury
in critically ill COVID-19 patients. Cytokine. 146:1555892021.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Martinez Valenzuela L, Draibe J, Bestard
O, Fulladosa X, Gómez-Preciado F, Antón P, Nadal E, Jové M, Cruzado
JM and Torras J: Urinary cytokines reflect renal inflammation in
acute tubulointerstitial nephritis: A multiplex bead-based assay
assessment. J Clin Med. 10:29862021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jakiela B, Kosałka J, Plutecka H, Węgrzyn
AS, Bazan-Socha S, Sanak M and Musiał J: Urinary cytokines and mRNA
expression as biomarkers of disease activity in lupus nephritis.
Lupus. 27:1259–1270. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu C, Chu D, Kalantar-Zadeh K, George J,
Young HA and Liu G: Cytokines: From clinical significance to
quantification. Adv Sci (Weinh). 8:e20044332021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cendrowski J, Mamińska A and Miaczynska M:
Endocytic regulation of cytokine receptor signaling. Cytokine
Growth Factor Rev. 32:63–73. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sugama K, Suzuki K, Yoshitani K, Shiraishi
K and Kometani T: Urinary excretion of cytokines versus their
plasma levels after endurance exercise. Exerc Immunol Rev.
19:29–48. 2013.PubMed/NCBI
|
|
29
|
Karagiannidis I, Salataj E, Said Abu Egal
E and Beswick EJ: G-CSF in tumors: Aggressiveness, tumor
microenvironment and immune cell regulation. Cytokine.
142:1554792021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu Z, Zhu Y, Wang Y, Fu Q, Fu H, Wang Z,
Zhang J, Li G, Xu J and Dai B: Prognostic value of granulocyte
colony-stimulating factor in patients with non-metastatic clear
cell renal cell carcinoma. Oncotarget. 8:69961–69971. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Monastero RN and Pentyala S: Cytokines as
biomarkers and their respective clinical cutoff levels. Int J
Inflam. 2017:43094852017.PubMed/NCBI
|
|
32
|
Raica M and Cimpean AM: Platelet-Derived
growth factor (PDGF)/PDGF receptors (PDGFR) Axis as target for
antitumor and antiangiogenic therapy. Pharmaceuticals. 3:572–599.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu KW, Hu B and Cheng SY:
Platelet-derived growth factor signaling in human malignancies.
Chin J Cancer. 30:581–584. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bartoschek M and Pietras K: PDGF family
function and prognostic value in tumor biology. Biochem Biophys Res
Commun. 503:984–990. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Powles T, Albiges L, Bex A, Grünwald V,
Porta C, Procopio G, Schmidinger M, Suárez C and de Velasco G; ESMO
Guidelines Committee. Electronic address, : simpleclinicalguidelines@esmo.org:
ESMO Clinical Practice Guideline update on the use of immunotherapy
in early stage and advanced renal cell carcinoma. Ann Oncol.
32:1511–1519. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Aldinucci D, Borghese C and Casagrande N:
The CCL5/CCR5 Axis in cancer progression. Cancers (Basel).
12:17652020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bai S, Wu Y, Yan Y, Kang H, Zhang J, Ma W,
Gao Y, Hui B, Li R, Zhang X and Ren J: The effect of CCL5 on the
immune cells infiltration and the prognosis of patients with kidney
renal clear cell carcinoma. Int J Med Sci. 17:2917–2925. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tokunaga R, Zhang W, Naseem M, Puccini A,
Berger MD, Soni S, McSkane M, Baba H and Lenz HJ: CXCL9, CXCL10,
CXCL11/CXCR3 axis for immune activation-A target for novel cancer
therapy. Cancer Treat Rev. 63:40–47. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wightman SC, Uppal A, Pitroda SP, Ganai S,
Burnette B, Stack M, Oshima G, Khan S, Huang X, Posner MC, et al:
Oncogenic CXCL10 signalling drives metastasis development and poor
clinical outcome. Br J Cancer. 113:327–335. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Qu G, Wang H, Yan H, Liu G and Wu M:
Identification of CXCL10 as a prognostic biomarker for clear cell
renal cell carcinoma. Front Oncol. 12:8576192022. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hunter CA and Jones SA: IL-6 as a keystone
cytokine in health and disease. Nat Immunol. 16:448–457. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Schumacher N, Schmidt S, Schwarz J, Dohr
D, Lokau J, Scheller J, Garbers C, Chalaris A, Rose-John S and Rabe
B: Circulating soluble IL-6R but Not ADAM17 activation drives
mononuclear cell migration in tissue inflammation. J Immunol.
197:3705–3715. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Rašková M, Lacina L, Kejík Z, Venhauerová
A, Skaličková M, Kolář M, Jakubek M, Rosel D, Smetana K Jr and
Brábek J: The role of IL-6 in cancer cell invasiveness and
metastasis-overview and therapeutic opportunities. Cells.
11:36982022. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kamińska K, Czarnecka AM, Escudier B, Lian
F and Szczylik C: Interleukin-6 as an emerging regulator of renal
cell cancer. Urol Oncol. 33:476–485. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hong IS: Stimulatory versus suppressive
effects of GM-CSF on tumor progression in multiple cancer types.
Exp Mol Med. 48:e242. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kumar A, Taghi Khani A, Sanchez Ortiz A
and Swaminathan S: GM-CSF: A Double-Edged sword in cancer
Immunotherapy. Front Immunol. 13:9012772022. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Werner S and Grose R: Regulation of wound
healing by growth factors and cytokines. Physiol Rev. 83:835–870.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Strang H, Kaul A, Parikh U, Masri L,
Saravanan S, Li H, Miao Q and Balaji S: Role of cytokines and
chemokines in wound healing. Wound Healing, Tissue Repair, and
Regeneration in Diabetes. Elsevier Academic Press; Cambridge, MA:
pp. 197–235. 2020, View Article : Google Scholar
|
|
49
|
Ray A: Cytokines and their Role in Health
and Disease: A Brief Overview. MOJ Immunol. 42016.
|
|
50
|
Kim HJ and Jung Y: The emerging role of
eosinophils as multifunctional leukocytes in health and disease.
Immune Netw. 20:e242020. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Coden ME and Berdnikovs S: Eosinophils in
wound healing and epithelial remodeling: Is coagulation a missing
link? J Leukoc Biol. 108:93–103. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Holmes DI and Zachary I: The vascular
endothelial growth factor (VEGF) family: Angiogenic factors in
health and disease. Genome Biol. 6:2092005. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Stojadinovic O, Kodra A, Golinko M,
Tomic-Canic M and Brem H: A Novel, Non-Angiogenic, Mechanism of
Vegf: Stimulation of Keratinocyte and Fibroblast Migration. Wound
Repair Regen. 15:A302007.PubMed/NCBI
|
|
54
|
Bao P, Kodra A, Tomic-Canic M, Golinko MS,
Ehrlich HP and Brem H: The role of vascular endothelial growth
factor in wound healing. J Surg Res. 153:347–358. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Nobles C, Bertone-Johnson ER, Ronnenberg
AG, Faraj JM, Zagarins S, Takashima-Uebelhoer BB and Whitcomb BW:
Correlation of urine and plasma cytokine levels among
reproductive-aged women. Eur J Clin Invest. 45:460–465. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Lippitz BE and Harris RA: Cytokine
patterns in cancer patients: A review of the correlation between
interleukin 6 and prognosis. Oncoimmunology. 5:e10937222016.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Blay JY, Negrier S, Combaret V, Attali S,
Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM,
Moskovtchenko JF, et al: Serum level of interleukin 6 as a
prognosis factor in metastatic renal cell carcinoma. Cancer Res.
52:3317–3322. 1992.PubMed/NCBI
|
|
58
|
Cechim G, Ellwanger JH, Kaminski V de L,
Berger M and Chies JAB: Increased systemic IL-6 levels point to
inflammation as a determinant of renal cell carcinoma development.
Clin Biomed Res. 41:1–211. 2021.
|
|
59
|
Negrier S, Perol D, Menetrier-Caux C,
Escudier B, Pallardy M, Ravaud A, Douillard JY, Chevreau C, Lasset
C and Blay JY; Groupe Francais d'Immunotherapie, : Interleukin-6,
Interleukin-10, and Vascular Endothelial Growth Factor in
Metastatic Renal Cell Carcinoma: Prognostic Value of
Interleukin-6-From the Groupe Français d'Immunothérapie. J Clin
Oncol. 22:2371–2378. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Wang Y and Zhang Y: Prognostic role of
interleukin-6 in renal cell carcinoma: A meta-analysis. Clin Transl
Oncol. 22:835–843. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Xu M, Wang Y, Xia R, Wei Y and Wei X: Role
of the CCL2-CCR2 signalling axis in cancer: Mechanisms and
therapeutic targeting. Cell Prolif. 54:e131152021. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Korbecki J, Grochans S, Gutowska I,
Barczak K and Baranowska-Bosiacka I: CC Chemokines in a Tumor: A
review of pro-cancer and anti-cancer properties of receptors CCR5,
CCR6, CCR7, CCR8, CCR9, and CCR10 ligands. Int J Mol Sci.
21:76192020. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Arakaki R, Yamasaki T, Kanno T, Shibasaki
N, Sakamoto H, Utsunomiya N, Sumiyoshi T, Shibuya S, Tsuruyama T,
Nakamura E, et al: CCL2 as a potential therapeutic target for clear
cell renal cell carcinoma. Cancer Med. 5:2920–2933. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Wang Z, Xie H, Zhou L, Liu Z, Fu H, Zhu Y,
Xu L and Xu J: CCL2/CCR2 axis is associated with postoperative
survival and recurrence of patients with non-metastatic clear-cell
renal cell carcinoma. Oncotarget. 7:51525–51534. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Yang Y, Zhai C, Chang Y, Zhou L, Shi T,
Tan C, Xu L and Xu J: High expression of chemokine CCL2 is
associated with recurrence after surgery in clear-cell renal cell
carcinoma. Urol Oncol. 34:238.e19–e26. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Lubowicka E, Przylipiak A, Zajkowska M,
Piskór BM, Malinowski P, Fiedorowicz W and Ławicki S: Plasma
chemokine CCL2 and its receptor CCR2 concentrations as diagnostic
biomarkers for breast cancer patients. Biomed Res Int.
2018:21243902018. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Izumi K, Mizokami A, Lin HP, Ho HM,
Iwamoto H, Maolake A, Natsagdorj A, Kitagawa Y, Kadono Y, Miyamoto
H, et al: Serum chemokine (CC motif) ligand 2 level as a
diagnostic, predictive, and prognostic biomarker for prostate
cancer. Oncotarget. 7:8389–8398. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Jin J, Lin J, Xu A, Lou J, Qian C, Li X,
Wang Y, Yu W and Tao H: CCL2: An important mediator between tumor
cells and host cells in tumor microenvironment. Front Oncol.
11:7229162021. View Article : Google Scholar : PubMed/NCBI
|
